Thursday, January 31, 2013
Publication and contact
Antigen-specific T cells
generated from induced pluripotent stem (iPS) cells derived for adoptive
Two separate groups showed
that iPS cells derived from mature CD8+ T cells can
be differentiated into antigen-specific T cells that may be useful for
overcoming T cell exhaustion during adoptive immunotherapy. Mature CD8+
T cells were reprogrammed into iPS cells and then differentiated into T cells
with the same functionality and antigen specificity as the original CD8+
T cells. One group used mature CD8+ T cells from an HIV-infected
patient to generate
T cells that showed antigen-specific activity against HIV p27 (nef). The other group used
CD8+ T cells from a patient with melanoma to generate T cells that
showed antigen-specific activity against melan-A (MLANA; MART1). Next steps for both
groups include testing the regenerated human T cells in animal models.
SciBX 6(4); doi:10.1038/scibx.2013.100
Published online Jan. 31, 2013
Patent application filed
for findings in first study; available for licensing from Megakaryon Corp.
Contact: Genjiro Miwa, Mgakaryon Corp., Tokyo, Japan
Findings in second study
unpatented; licensing status not applicable
Nishimura, T. et al.
Cell Stem Cell; published online Jan. 3, 2013;
Contact: Hiromitsu Nakauchi, The University of Tokyo, Tokyo,
Vizcardo, R. et al. Cell Stem Cell; published online Jan. 3, 2013;
Contact: Hiroshi Kawamoto, RIKEN Research Center for Allergy
and Immunology, Yokohama, Japan
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]